美国 · SEC FORM 4
ImmunityBio, Inc.
IBRX · Nasdaq · CIK 0001326110 · Healthcare · Biotechnology
内部人信号
0 qualifying P purchase groups
当前 180 天评分窗口
17 同一窗口内观察到的 Form 4 交易行
8 sales · 9 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号?
评分构成
活跃窗口内没有合资格买入,因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数?
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示,不会形成负分。
卖出和其他 Form 4 活动会单独显示,不会形成负面买入信号。没有买入不会被评分为看空。
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后,这些模块才会启用。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型;卖出仅作为背景。
—
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2023-06-05 · BLASZYK MICHAEL D.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据,不影响内部人信号。
- 空头股数
- 124,092,202
- 上期报告
- 125,408,192
- 日均成交量
- 13,967,506
- 回补天数
- 8.9
FINRA 结算日:2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数,每月两个结算日之后约一周公布;不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2023-06-05 | BLASZYK MICHAEL D | 买入 (P) | Common Stock | 71,915 | USD 2.75 | USD 198,023 | SEC 申报 ↗ |
| 2023-06-02 | Brennan John Owen | 买入 (P) | Common Stock | 25,000 | USD 2.83 | USD 70,700 | SEC 申报 ↗ |
| 2023-06-01 | Clark Wesley | 买入 (P) | Common Stock | 7,000 | USD 2.91 | USD 20,370 | SEC 申报 ↗ |
| 2021-10-08 | Adcock Richard | 买入 (P) | Common Stock | 1,930 | USD 8.81 | USD 17,005 | SEC 申报 ↗ |
| 2020-06-29 | Cambridge Equities, LP; MP 13 Ventures, LLC; SOON-SHIONG PATRICK | 买入 (P) | Common Stock | 3,710,000 | USD 12.12 | USD 44,965,200 | SEC 申报 ↗ |
Form 4 申报证据
50 transaction lines in the latest 365-day window; 175 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-10-05 | Simon Barry J. | 卖出 (S) | Common Stock | 25,000 | USD 10.75 | USD 268,760 | SEC 申报 ↗ |
| 2026-10-02 | Cohen Cheryl | 卖出 (S) | Common Stock | 81,056 | USD 10.50 | USD 851,088 | SEC 申报 ↗ |
| 2026-10-02 | Cohen Cheryl | 期权行权/转换 (M) | Common Stock | 55,979 | USD 2.98 | USD 166,817 | SEC 申报 ↗ |
展开近期 Form 4 证据 (30 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-10-05 | Simon Barry J. | 卖出 (S) | Common Stock | 25,000 | USD 10.75 | USD 268,760 | SEC 申报 ↗ |
| 2026-10-02 | Cohen Cheryl | 卖出 (S) | Common Stock | 81,056 | USD 10.50 | USD 851,088 | SEC 申报 ↗ |
| 2026-10-02 | Cohen Cheryl | 期权行权/转换 (M) | Common Stock | 55,979 | USD 2.98 | USD 166,817 | SEC 申报 ↗ |
| 2026-07-02 | Cohen Cheryl | 卖出 (S) | Common Stock | 131,210 | USD 9.50 | USD 1,246,495 | SEC 申报 ↗ |
| 2026-07-02 | Cohen Cheryl | 期权行权/转换 (M) | Common Stock | 55,979 | USD 2.98 | USD 166,817 | SEC 申报 ↗ |
| 2026-07-01 | Selecky Christobel | 卖出 (S) | Common Stock | 159,478 | USD 9.02 | USD 1,438,492 | SEC 申报 ↗ |
| 2026-07-01 | Selecky Christobel | 期权行权/转换 (M) | Common Stock | 159,478 | USD 2.99 | USD 476,489 | SEC 申报 ↗ |
| 2026-06-30 | Selecky Christobel | 卖出 (S) | Common Stock | 1,000 | USD 9.00 | USD 9,000 | SEC 申报 ↗ |
| 2026-06-30 | Selecky Christobel | 期权行权/转换 (M) | Common Stock | 1,000 | USD 2.98 | USD 2,983 | SEC 申报 ↗ |
| 2026-06-29 | Selecky Christobel | 卖出 (S) | Common Stock | 95,722 | USD 9.01 | USD 862,455 | SEC 申报 ↗ |
| 2026-06-29 | Selecky Christobel | 期权行权/转换 (M) | Common Stock | 95,722 | USD 2.94 | USD 281,387 | SEC 申报 ↗ |
| 2026-06-24 | Simon Barry J. | 卖出 (S) | Common Stock | 25,000 | USD 7.88 | USD 197,000 | SEC 申报 ↗ |
| 2026-06-04 | Simon Barry J. | 卖出 (S) | Common Stock | 23,033 | USD 7.18 | USD 165,377 | SEC 申报 ↗ |
| 2026-02-24 | Simon Barry J. | 卖出 (S) | Common Stock | 75,000 | USD 12.01 | USD 900,750 | SEC 申报 ↗ |
| 2026-02-23 | Simon Barry J. | 卖出 (S) | Common Stock | 165,000 | USD 10.25 | USD 1,691,250 | SEC 申报 ↗ |
| 2026-02-23 | Selecky Christobel | 卖出 (S) | Common Stock | 25,000 | USD 10.00 | USD 250,000 | SEC 申报 ↗ |
| 2026-02-23 | Selecky Christobel | 期权行权/转换 (M) | Common Stock | 25,000 | USD 2.98 | USD 74,500 | SEC 申报 ↗ |
| 2026-02-22 | Simon Barry J. | 期权行权/转换 (M) | Common Stock | 15,243 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-22 | Simon Barry J. | 代扣税 (F) | Common Stock | 6,026 | USD 8.70 | USD 52,426 | SEC 申报 ↗ |
| 2026-02-22 | Sachs David C. | 期权行权/转换 (M) | Common Stock | 40,650 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-22 | Sachs David C. | 代扣税 (F) | Common Stock | 20,682 | USD 8.70 | USD 179,933 | SEC 申报 ↗ |
| 2026-02-22 | LAUER REGAN J | 期权行权/转换 (M) | Common Stock | 4,065 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-22 | LAUER REGAN J | 代扣税 (F) | Common Stock | 1,673 | USD 8.70 | USD 14,555 | SEC 申报 ↗ |
| 2026-02-22 | CALIFORNIA CAPITAL EQUITY, LLC; Cambridge Equities, LP; MP 13 Ventures, LLC; Nant Capital, LLC; SOON-SHIONG PATRICK | 期权行权/转换 (M) | Common Stock | 114,329 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-22 | CALIFORNIA CAPITAL EQUITY, LLC; Cambridge Equities, LP; MP 13 Ventures, LLC; Nant Capital, LLC; SOON-SHIONG PATRICK | 代扣税 (F) | Common Stock | 58,170 | USD 8.70 | USD 506,079 | SEC 申报 ↗ |
| 2026-02-22 | Adcock Richard | 期权行权/转换 (M) | Common Stock | 152,439 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-22 | Adcock Richard | 代扣税 (F) | Common Stock | 77,560 | USD 8.70 | USD 674,772 | SEC 申报 ↗ |
| 2026-02-20 | Simon Barry J. | 卖出 (S) | Common Stock | 10,000 | USD 9.25 | USD 92,500 | SEC 申报 ↗ |
| 2026-02-10 | Sachs David C. | 期权行权/转换 (M) | Common Stock | 82,236 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-10 | Sachs David C. | 代扣税 (F) | Common Stock | 42,643 | USD 6.93 | USD 295,516 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-19 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | IBRX |
| CIK | 0001326110 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2836 Biological Products, (No Diagnostic Substances) |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 175 transaction lines from 2020-03-23 to 2026-10-05 10 P purchase lines · 52 S sale lines · 113 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-19. Mapping status is an audit field and does not erase SEC filing evidence.